Trevi Therapeutics Statistics
Share Statistics
Trevi Therapeutics has 76.87M shares outstanding. The number of shares has increased by 13.68% in one year.
| Shares Outstanding | 76.87M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.06% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 45.60M |
| Failed to Deliver (FTD) Shares | 165.00K |
| FTD / Avg. Volume | 10.77% |
Short Selling Information
The latest short interest is 1.72M, so 2.23% of the outstanding shares have been sold short.
| Short Interest | 1.72M |
| Short % of Shares Out | 2.23% |
| Short % of Float | 3.92% |
| Short Ratio (days to cover) | 3.78 |
Valuation Ratios
The PE ratio is -4.57 and the forward PE ratio is -6.32.
| PE Ratio | -4.57 |
| Forward PE | -6.32 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.61 |
| P/FCF Ratio | -4.17 |
| PEG Ratio | n/a |
Enterprise Valuation
Trevi Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 15.03, with a Debt / Equity ratio of 0.
| Current Ratio | 15.03 |
| Quick Ratio | 15.03 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.37 |
| Cash Flow / Debt | -103.63 |
| Interest Coverage | -86.76 |
Financial Efficiency
Return on equity (ROE) is -0.35% and return on capital (ROIC) is -40.4%.
| Return on Equity (ROE) | -0.35% |
| Return on Assets (ROA) | -0.33% |
| Return on Capital (ROIC) | -40.4% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.08M |
| Employee Count | 27 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -32.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 225.78% in the last 52 weeks. The beta is 1.01, so Trevi Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | 225.78% |
| 50-Day Moving Average | 2.97 |
| 200-Day Moving Average | 2.94 |
| Relative Strength Index (RSI) | 66.98 |
| Average Volume (20 Days) | 1.53M |
Income Statement
In the last 12 months, Trevi Therapeutics had revenue of $0 and earned -$29.07M in profits. Earnings per share was $-0.29.
| Revenue | 0 |
| Gross Profit | -123.00K |
| Operating Income | -33.92M |
| Net Income | -29.07M |
| EBITDA | -33.80M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.29 |
Balance Sheet
The company has $32.40M in cash and $1.34M in debt, giving a net cash position of $31.06M.
| Cash & Cash Equivalents | 32.40M |
| Total Debt | 1.34M |
| Net Cash | 31.06M |
| Retained Earnings | -239.13M |
| Total Assets | 68.91M |
| Working Capital | 58.21M |
Cash Flow
In the last 12 months, operating cash flow was -$31.71M and capital expenditures -$137.00K, giving a free cash flow of -$31.85M.
| Operating Cash Flow | -31.71M |
| Capital Expenditures | -137.00K |
| Free Cash Flow | -31.85M |
| FCF Per Share | -0.32 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TRVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.95% |
| FCF Yield | -9.94% |
Analyst Forecast
The average price target for TRVI is $7.5, which is 79.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.5 |
| Price Target Difference | 79.9% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 10 |
| Piotroski F-Score | 2 |